

BEST AVAILABLE COPY

Treatment of Malignant Endocrine Pancreatic Tumors with a New Long-Acting Somatostatin Analogue, SMS 201-995

B. ERIKSSON, K. ÖBERG, T. ANDERSSON, G. LUNDQVIST, L. WIDE & E. WILANDER

Ludwig Institute for Cancer Research, Uppsala Branch, Clinical Group, and Dept. of Internal Medicine, Radiology, Clinical Chemistry, and Pathology, University Hospital, Uppsala, Sweden

Eriksson B, Öberg K, Andersson T, Lundqvist G, Wide L, Wilander E. Treatment of malignant endocrine pancreatic tumors with a new long-acting somatostatin analogue, SMS 201-995. *Scand J Gastroenterol* 1988; 23: 508-512

Ten patients with malignant endocrine pancreatic tumors were treated with SMS 201-995 at doses of 50 µg twice daily, administered subcutaneously. Four out of 10 patients (40%)—1 patient with the Zollinger-Ellison syndrome and 3 of 6 with the watery diarrhea syndrome—responded objectively with more than 50% reduction of peptide levels, with a median duration of 15.5 months. All four patients improved symptomatically, with decreasing dyspeptic symptoms and decreasing diarrhea. Three additional patients had a clear relief of symptoms without an effect on tumor-secreted peptides. The disease progressed in three patients during treatment. No reduction of tumor mass was seen in any of the patients. The main side effect noted was a slight but maintained increase in fasting blood glucose in four patients. In conclusion, SMS 201-995 had a beneficial effect in more than half of the patients and seems to be a valuable adjunct to other causal therapy in this patient category, especially in acute situations and weak patients because of its very few side effects.

Key words: Endocrine pancreatic tumors, malignant; somatostatin analogue SMS 201-995; tumor therapy

Barbro Eriksson, M.D., Ludwig Institute for Cancer Research, Uppsala Branch, Clinical Group, University Hospital, S-751 85 Uppsala, Sweden

Somatostatin is a naturally occurring peptide with a wide distribution in the body.

Because of its inhibitory effects, native somatostatin has been used therapeutically in various hypersecretory conditions in the gastrointestinal tract. In 1983 we could demonstrate the inhibition of tumor-secreted insulin and gastrin in a benign insulinoma and malignant gastrinoma (1). One disadvantage with native somatostatin is its short plasma half-life, only 2–3 min, which necessitates intravenous infusion (2). Another problem is the rebound phenomenon that occurs when the infusion is stopped (3).

A new long-acting somatostatin analogue, a cyclic octapeptide, SMS 201-995 (Sandoz, Basel, Switzerland) has recently become available (4).

It is more resistant to enzymatic degradation than the native compound, and its plasma half-life when given intravenously is approximately 60 min (5). It can also be administered subcutaneously, and its plasma half-life is then approximately 2 h (5). SMS 201-995 has been shown to be much more potent than the native compound, and it selectively suppresses growth hormone (GH) and glucagon levels more than insulin levels (5).

There are reports of beneficial effects of SMS 201-995 in cases of malignant endocrine pancreatic tumors (6–13), but the experience is still very limited. We thus want to report the effect of this long-acting somatostatin analogue in the management of 10 patients with malignant endocrine pancreatic tumors.

SUBJECTS AND METHODS

Patients

Ten patients, eight men and two women, with a mean age of 64.7 years (range, 51–75) were included in the study. Most of them had tumors with multiple peptide secretion. The peptide considered to be causing the syndrome was called the 'main' tumor. One patient had the Zollinger-Ellison syndrome, whereas six had the watery diarrhea syndrome. One patient had a malignant insulinoma, and the other two had no specific tumors—that is, they had no specific related symptoms. Two patients with the watery diarrhea syndrome had a MEN-1 trait. Seven patients had remaining pancreatic tumor, and one had metastases. One patient had lung metastases.

Five patients had been subjected to surgery. Embolization of liver metastases had been undertaken in one case. Seven patients received chemotherapy, mainly streptozotocin or doxorubicin (7), with initial responses but then progressive disease. These seven patients had been treated with human leukocyte interferon, and therapy with SMS 201-995 was started. Two patients had received radiation therapy because of their poor general condition, and chemotherapy and interferon were impossible.

Methods

Fasting peripheral blood samples were collected before and during SMS 201-995 treatment. Insulin, proinsulin, c-peptide, gastrin, chorionic gonadotropin (HCG) and its subunits (15), pancreatic polypeptide, calcitonin (17), plasma vasoactive peptide (VIP) (18), glucagon (19), (20), and neuropeptides (21) were measured by radioimmunoassays described elsewhere (15). Hematology, liver enzymes, blood glucose, T₄, and thyroid-stimulating hormone assays were checked before and during treatment. Histopathologic diagnosis was made by biopsy.

Pancreatic Tumors Analogue,

E &

Wide L, Wilander E. Treatment of long-acting somatostatin analogue, 18-512

Tumors were treated with SMS 201-995 subcutaneously. Four out of 10 patients from whom 3 of 6 with the watery diarrhea had more than 50% reduction of peptide. All four patients improved symptoms and decreasing diarrhea. Three without an effect on tumor-secreted peptides during treatment. No reduction in main side effect noted was a slight decrease in four patients. In conclusion, SMS 201-995 seems to be a good treatment for patients and seems to be a good treatment category, especially in acute side effects.

ant; somatostatin analogue SMS

Cancer Research, Uppsala Branch, Uppsala, Sweden

o enzymatic degradation than insulin, and its plasma half-life is approximately 60 min. When administered subcutaneously, its half-life is then approximately 2 h. It has been shown to be much longer than the native compound, and it is longer than growth hormone (GH) and insulin (5).

The beneficial effects of SMS 201-995 in malignant endocrine pancreatic tumors (3), but the experience is still limited. We want to report the effect of somatostatin analogue in the patients with malignant endocrine tumors.

SUBJECTS AND METHODS

Patients

Ten patients, eight men and two women, with a mean age of 64.7 years (range, 54–73 years) were included in the study. Most of the patients had tumors with multiple peptide secretion, but the peptide considered to be causing the clinical syndrome was called the 'main' tumor marker. One patient had the Zollinger-Ellison syndrome, whereas six had the watery diarrhea (WDHA) syndrome. One patient had a malignant insulinoma, and the other two had non-functioning tumors—that is, they had no specific hormone-related symptoms. Two patients with the WDHA syndrome had a MEN-1 trait. Seven patients had a remaining pancreatic tumor, and eight had liver metastases. One patient had lung metastases.

Five patients had been subjected to pancreatic surgery. Embolization of liver metastases had been undertaken in one case. Seven patients had received chemotherapy, mainly streptozocin plus 5-fluorouracil or doxorubicin (Adriamycin®), with initial responses but then failure of this treatment. These seven patients had also been treated with human leukocyte interferon with responses of various duration but were showing progressive disease when SMS 201-995 was started. Two patients had received no prior treatment, and therapy with SMS 201-995 was started because of their poor general condition, which made chemotherapy and interferon treatment impossible.

Methods

Fasting peripheral blood samples were collected before and during SMS therapy. Serum insulin, proinsulin, c-peptide, gastrin (14), human chorionic gonadotropin (HCG) alpha and beta subunits (15), pancreatic polypeptide (PP) (16), calcitonin (17), plasma vasoactive intestinal polypeptide (VIP) (18), glucagon (19), somatostatin (20), and neurotensin (21) were analyzed by radioimmunoassays described earlier. Routine hematology, liver enzymes, blood glucose, serum T₄, and thyroid-stimulating hormone (TSH) assays were checked before and regularly during treatment. Histopathologic diagnosis was estab-

lished in all 10 cases on tissue specimens taken at surgery or by coarse-needle biopsy (22). All tumors were argyrophil with the Grimelius silver nitrate stain (23). Routinely fixed, paraffin-embedded sections were immunohistochemically investigated with antibodies against gastrin, insulin, PP, glucagon, somatostatin, HCG alpha, HCG beta, calcitonin, VIP, and neuropeptides (24).

SMS 201-995

SMS 201-995, the long-acting cyclic octapeptide produced by Sandoz, was administered as daily subcutaneous injections at initial doses of 50 µg twice daily. In seven of the patients increased doses were required.

Evaluation of tumor response

In the evaluation of the therapeutic effect, *objective response* was defined as a reduction of the 'main' tumor markers and/or tumor size by >50%. *Stable disease* was defined as a reduction of the main tumor marker and/or tumor mass by <50% and no appearance of new metastases. *Progressive disease* was defined as an increase in tumor markers and/or tumor mass by >25% or appearance of new metastases.

RESULTS

Objective responses were seen in 4 of 10 patients (40%) treated with SMS 201-995 (Table I). The mean duration of the response was 13.5 months (median, 15.5 months; range, 5–18 months). All four patients had a reduction of the main tumor marker by more than 50% (one patient with the Zollinger-Ellison syndrome and three of six with the WDHA syndrome). No patient had a reduction of tumor mass. However, tumor size remained unchanged on computed tomography (CT) scans in all patients during the observation time (mean, 9 months). Three patients had stable disease with a mean duration of 4.3 months. In three of the patients with objective response and in two of the patients with stable disease the somatostatin dose was increased up to 200 µg/day within 2–14 months to maintain the effect. Progressive disease was noted in the other three patients.

Symptomatically, 7 of the 10 patients (70%)

Table I. Patients with malignant endocrine pancreatic tumors treated with SMS 201-995

Patient no.	Clinical syndrome*	Earlier treatment†	Duration of disease	SMS treatment: hormone levels‡	Duration of therapy	Duration of objective response	Sympt. effect	Adverse effect
				Before	After			
1	Z-E	CT; IFN	120 mo	Gastrin, 194 pmol/l No measurable marker	35.3 pmol/l	18 mo	—	Slight diabetes
2	WDHA	CT; IFN	32 mo	Calc, 18,000 ng/l	9000 ng/l	6 mo	—	Abd. pain + fever
3	WDHA	CT; IFN	38 mo	Calc, 420 ng/l	660 ng/l	16 mo	—	Higher insulin dose
4	Non-f	None	120 mo	PP, 14.2 ng/l	7.0 ng/l	19 mo	—	Slight diabetes
5	WDHA	CT; IFN	84 mo	Calc, 470 ng/l	180 ng/l	5 mo	—	Slight diabetes
6	WDHA	CT; IFN	156 mo	Calc, 470 ng/l	15 mo	15 mo	—	Slight diabetes, hypocalcemia
7	WDHA	None	4 mo	VIP, 190 pmol/l	190 pmol/l	2 mo	—	—
8	Hypoglycemia	None	2 mo	Insulin, 129 mU/l	102 mU/l	2 days	—	Lower b-glucose
9	Non-f	CT; IFN	36 mo	PP, 1.85 ng/ml	2.7 ng/ml	1 mo	—	—
10	WDHA	CT; IFN	76 mo	VIP, 37.6	73.8	6 mo	—	Abd. pain + fever

* Z-E = Zollinger-Ellison; WDHA = water diarrhea hypokalemia achlorhydria; non-f = non-functioning tumor.

† CT = chemotherapy; IFN = human leukocyte interferon.

‡ Calc = calcitonin; PP = pancreatic polypeptide; VIP = vasoactive intestinal polypeptide.

improved. As is shown in Table I, five patients with the WDHA syndrome, one with the Zollinger-Ellison syndrome, and one with a non-functioning tumor responded subjectively.

One of the patients who did not respond had a VIPoma, which also produced large amounts of endogenous somatostatin. In this case we attempted doses as high as 100 µg/h intravenously without achieving an effect.

In the four patients with objective response, all with multiple peptide secretion, the main marker decreased, while the other peptides increased. There was a discrepancy in the inhibiting effect on the release of different peptides.

Another observation could be made in two patients (cases 3 and 4), whose tumors had no known production of gastrin. During treatment with SMS 201-995 serum gastrin levels increased in both, while the tumor markers decreased. Basal acid output was measured in one of them and was shown to be very low.

Adverse effects

The side effects with this somatostatin analogue are remarkably few. We noticed a slight increase in fasting blood glucose (1.8 ± 1.1 (SD) mmol/l) in 4 of the 10 patients (Table I). One patient with insulin-treated diabetes required a higher insulin dose. Another patient with a malignant insulinoma received SMS 201-995 during the first 24 h in hospital, but blood glucose levels rather decreased, and alternative treatment had to be initiated. No patient developed clinically significant diarrhea or steatorrhea, probably because we used a relatively low dosage and because eight patients received pancreatic enzymes prophylactically. The existence of a subclinical malabsorption or steatorrhea cannot be excluded, since fat excretion was not routinely measured. Two patients with the WDHA syndrome, both of whom had been subjected to extensive abdominal surgery (in one case by the method of Whipple), developed abdominal pain and fever attacks, which were interpreted as attacks of cholangitis. Decreased intestinal motility caused by the analogue could explain these attacks. In both patients SMS 201-995 was withdrawn, and in one the adverse symptoms decreased within 3 days, and

SMS 201-995 could be reinitiated in a dose. Pain at the injection site was a patients who received higher doses.

One patient with MEN-1 and the syndrome was maintained on a low subs of calcium after surgery for hyperparathyroidism and developed severe hypocalcemia (reference level, 2.20–2.60) 3 month after initiation of SMS, and vitamin D substitut was added. Parathyroid hormone (PTH) remained unchanged. The hypocalcemia in this patient could reflect intestinal inhibition of calcium absorption by the analog. Hormone or liver enzyme values or laboratory results were not altered by the treatment.

DISCUSSION

The optimal treatment in malignant pancreatic tumors has not yet been established. Surgery is the primary form of treatment, but because most patients have inoperable disease, other forms of therapy must be considered. Chemotherapy produces responses in >60% of patients with endocrine pancreatic tumors (E 19). The median duration of response of 17 months is similar to that of human leukocyte interferon (20). Human leukocyte interferon has shown to give objective responses in patients with malignant EPT, with a median duration of 8.5 months (27). How the treatments cure the disease, and what treatments are needed.

There are already several reports of the beneficial effects of SMS 201-995 in patients with malignant EPT. Improvement in symptoms, reduction of peptide levels, and, in some cases, reduction of tumor mass have been reported (12).

In our study SMS 201-995 was given to patients with advanced disease, and cytotoxics and interferon no longer controlled the disease. In two patients the somatostatin antagonist was the only treatment that the patients could tolerate because of their poor clinical condition.

In more than half of our patients the treatment had a beneficial effect, with subjective responses in seven patients.

shown in Table I, five patients responded subjectively. Patients who did not respond had also produced large amounts of somatostatin. In this case we used as high as 100 µg/h intravenously without effect.

Patients with objective response, all due to secretion, the main marker for the other peptides increased discrepancy in the inhibiting effect of different peptides.

Treatment could be made in two stages (4), whose tumors had no gastrin. During treatment serum gastrin levels increased and tumor markers decreased. Basal insulin was measured in one of them and was normal.

With this somatostatin analogue

We noticed a slight increase in serum gastrin (1.8 ± 1.1 (SD) mmol/l) (Table I). One patient with gastrinoma required a higher insulin dose with a malignant insulinoma during the first 24 hours. Blood glucose levels rather than alternative treatment had to be developed clinically significant hypoglycemia, probably because of low dosage and because eight pancreatic enzymes prophylaxis of a subclinical malabsorption cannot be excluded, since they were not routinely measured. Two DHA syndrome, both of which led to extensive abdominal pain and fever attacks, d

as attacks of cholangitis, and nocturnal caused by the analgesic attacks. In both patients withdrawn, and in one the pain was relieved within 3 days, and

SMS 201-995 could be reinitiated in an escalating dose. Pain at the injection site was a complaint in patients who received higher doses.

One patient with MEN-1 and the WDHA syndrome was maintained on a low substitution dose of calcium after surgery for hyperparathyroidism and developed severe hypocalcemia (1.61 mmol/l reference level, 2.20–2.60) 3 months after initiation of SMS, and vitamin D substitution therapy was added. Parathyroid hormone (PTH) levels remained unchanged. The hypocalcemia in this patient could reflect intestinal inhibition of calcium absorption by the analogue. Thyroid hormone or liver enzyme values or routine hematology results were not altered by the treatment.

DISCUSSION

The optimal treatment in malignant endocrine pancreatic tumors has not yet been established. Surgery is the primary form of treatment (25), but because most patients have inoperable metastasizing disease, other forms of therapy have to be considered. Chemotherapy produces objective responses in >60% of patients with malignant endocrine pancreatic tumors (EPT) with a median duration of response of 17 months (26). Human leukocyte interferon has recently been shown to give objective responses in 77% of patients with malignant EPT, with a median duration of 8.5 months (27). However, none of the treatments cure the disease, and alternative treatments are needed.

There are already several reports about the beneficial effects of SMS 201-995 in the treatment of malignant EPT. Improvement of symptoms, reduction of peptide levels, and, in isolated cases, reduction of tumor mass have been described (6–12).

In our study SMS 201-995 was attempted in 10 patients with advanced disease, in which both cytotoxics and interferon no longer had an effect. In two patients the somatostatin analogue was the only treatment that the patients could tolerate because of their poor clinical condition.

In more than half of our patients the treatment had a beneficial effect, with symptomatic and subjective responses in seven patients. In 4 out of

10 patients (40%) SMS 201-995 reduced the levels of tumor-produced peptides by more than 50%, with a median duration of 15.5 months. However, with time higher doses seemed to be required to keep the peptide levels down and clinical symptoms away. Six patients required a dose increase after 2–14 months of up to 200 µg/day. The patients seem to develop tachyphylaxis, which might be due to down-regulation of somatostatin receptors. In one patient with a somatostatin-producing VIPoma, 100 µg/h intravenously was tried without any effect. The therapy resistance in this particular case should be noted, since concomitant somatostatin production from a tumor probably down-regulates somatostatin receptors. This mechanism for therapy resistance to SMS 201-995 has not been reported earlier. The observation that symptomatic improvement persisted in spite of increasing peptide levels or occurred without accompanying decrease in tumor markers has also been made by others (12). This discrepancy between objective and symptomatic response could reflect the proportionally stronger and longer-lasting effect of SMS 201-995 on peripheral target organs—that is, the mucosa of the stomach and the intestine described in earlier reports (10). The increase in serum gastrin in two of our patients during treatment could also be an expression of this phenomenon. Decreased basal acid output was demonstrated in one of these two patients but not measured in the other.

Whether SMS 201-995 has an effect on tumor growth is still not known. In the present study no patient had a reduction of tumor mass. On the other hand, no increase in tumor size was seen on CT scan, which could indicate an inhibitory effect on tumor cell growth. In animal models, SMS 201-995 has been reported to have moderate but significant inhibitory effects on the growth of transplanted peptide-producing tumors (28). There have been reports in the literature about possible shrinkage of metastases of EPT during treatment with SMS 201-995 (13), but these observations need confirmation in additional studies of patients. Since SMS 201-995 does not exert cytostatic effects, the inhibited growth might be due to inhibition of autocrine and/or endocrine growth factors.

The optimal dose of the analogue is not yet clear. We have used a relatively low dose compared with others, and higher doses might improve the results. We attempted higher doses in some of our patients, and they tolerated these doses well (100 µg/h intravenously). SMS 201-995 has relatively few adverse effects. The occurrence of steatorrhea, an observed side effect in other reports (29), was not thoroughly studied in this patient material. Hypocalcemia, attacks of cholangitis, and the worsening of hypoglycemia seen in the insulinoma patient deserve mention.

In conclusion, the analogue seems to have dual effects, acting both directly on tumor-produced peptide release and indirectly on the peripheral target organs of the peptides. Even though some patients do not respond objectively to the treatment, there may be a beneficial and ameliorating effect on peptide-related symptoms, which is an important goal in the treatment of this patient category. In the management of patients with malignant endocrine pancreatic tumors, SMS 201-995 will probably be a valuable complement to chemotherapy and interferon treatment, especially in acute stages of the disease and in elderly, weak patients because of its very few side effects.

REFERENCES

- Öberg K. Upsala J Med Sci 1983(suppl 39), 107-130
- Sheppard M, Shapiro B, Primstone B, Kronheim S, Berelowitz M, Gregory M. J Clin Endocr Metab 1979, 48, 50-53
- Besser GM, Mortimer CH, Carr D, Schally AV, Coy DH, Ewered D, Kastin AJ, et al. Br Med J 1974, 1, 352-355
- Bauer W, Briner U, Doeppner W, et al. Life Sci 1982, 31, 1133-1141
- del Pozo GM, Schlüter K, Neufeld M, et al. Acta Endocrinol (in press)
- Ellison EC, Woltering EA, O'Dorisio TM. Gastroenterology 1985, 88, 1371
- Tsai ST, Lewis EM, Vinik AI. Clin Res 1985, 33, 876A
- Maton PN, O'Dorisio TM, Howe BA. N Engl J Med 1985, 312, 17-21
- Kann CR, Bahathena SJ, Recant L, Rivier J. J Clin Endocrinol Metab 1981, 53, 543-549
- Ellison EC, O'Dorisio TM, Sparks J, Mekhjian HS, Fromkes JJ, Woltering EA, Casey LC. Surgery 1986, 100, 437-444
- Mulvihill S, Pappas TN, Passaro E Jr, Debas HT. Surgery 1986, 100, 167-176
- Wood SW, Kraenzlin ME, Adrian TE, Bloom SR. Gut 1985, 26, 438-444
- Cleménçis D, Elías E. Lancet 1985; i, 874-875
- Lundqvist G, Wide L. Clin Chim Acta 1977, 79, 357-362
- Wide L. Acta Endocrinol (Copenh) 1969, 142, 207-221
- Hälgren R, Lundqvist G, Chance RE. Scand J Gastroenterol 1977, 12, 923-927
- Almgvist S, Telenius-Berg M, Wästhed B. Acta Med Scand 1974, 196, 177-180
- Fahrenkrug J, Schaffalitzky de Muckadell OB, J Lab Clin Med 1977, 89, 1379-1388
- Unger RH, Aquillard-Parada E, Muller WA, Eisentraut AM. J Clin Invest 1970, 49, 837-848
- Arimura A, Lundqvist G, Rothman J, Chang R, Fernandez-Durango R, Elde R, Coy HD, et al. Metabolism 1978, 27, 1139-1144
- Theodorsson-Norheim E, Öberg K, Rosell S, Bostrom H. Gastroenterology 1983, 85, 881-889
- Lindgren PG. Acta Radiol Diagn 1982, 23, 653-656
- Grimelius L, Wilander E. Invest Cell Pathol 1980, 3, 2-12
- Sternberger LA. Immunocytochemistry. Prentice Hall Inc., Englewood Cliffs, NJ, 1974
- Wellbourn RB, Wood SM, Polak JM, Bloom SR. In: Bloom SR, Polak JM, eds. Gut hormones. 2nd ed. Churchill Livingstone, London, 1981, 547-554
- Moertel CG, Hanley JA, Johnson LA. N Engl J Med 1980, 303, 1189-1194
- Eriksson B, Öberg K, Alm G, Karlsson A, Lundqvist G, Andersson T, Wide L, Wilander E. Lancet 1986, 2, 1307-1308
- Reubi JC. Acta Endocrinol 1985, 109, 108-114
- Plewe G, Schrenzmeir J, Nölken G, Krause U, Beyer J, Kasper H, del Pozo E. Klin Wochenschr 1986, 64, 389-392

Received 10 September 1987

Accepted 11 January 1988

MANUSCRIPTS

The manuscript shall be clearly typewritten, in English only, with double spacing throughout and with 3 cm.

Begin each of the following sections on separate pages and key words, text, acknowledgements, references, figure legends. Number the pages consecutively, beginning page. The text should normally be divided into introduction, results, and discussion. Use a clear system of headings. The text with not more than three grades of headings. Position of all figures and tables should be indicated. Manuscripts must be submitted in final, fully corrected form; proofs are expensive, and authors will be required to make such alterations. The original manuscript shall be submitted in triplicate copies, on the express condition that it has simultaneously submitted, or already accepted for publication. When reporting experiments on human subjects, indicate what procedures followed were in accordance with the ethical committee on human experimentation of the institution where the work was done, and in accordance with the Declaration of Helsinki. Authors should include a statement verifying that the animals followed accepted standards.

Articles should not exceed 6 printed pages. A page will be made for each printed page or part thereof if necessary.

TITLE PAGE

The title page shall contain:

- The title of the article, which should be concise. Subtitles may be used if necessary, but must be brief.
- A short title not exceeding 40 letters and space available.
- The full name of each author.
- The departments and institutions to which the work was attributed and their addresses.

ABSTRACTS AND KEY WORDS

An abstract not exceeding 150 words should be printed. When printed, the text should not exceed 1 page. It should state briefly the object of the investigation, methods, findings, and principal conclusions. Only standard abbreviations should be used. Above the abstract type the authors' names in accordance with the style of the journal. Not more than four names should be inserted in alphabetical order below the abstract. The name and current address of the author corresponding to the correspondence, proofs, and offprints are to be added below the key words.

ACKNOWLEDGEMENT

Acknowledge only persons who have made substantial contributions to the study. Authors are responsible for obtaining the names and addresses of everyone acknowledged by name because readers may wish to contact them. The source of grants, etc., should be acknowledged here.

TABLES

Type each table, double-spaced, on a separate sheet. Give each table a short descriptive heading. Give each table an abbreviation. Place explanatory matter in the heading. Explain in the footnotes all not used in the table. For footnotes, use the following symbols: *, †, ‡, §, ||, ¶, **, ††, etc.

Omit internal horizontal and vertical rules (line). If published or unpublished sources are used, obtain permission to use them. A table shall as far as possible be self-explanatory and stand alone without reference to the text of the article.

FIGURES

All illustrations are to be considered as figures. Figures should be numbered consecutively with Arabic numbers, and symbols must be clear, in proportion large enough to be legible when reduced for publication. The author should refer to the journal and decide whether one, one-and-a-half, or two columns of text are to be used and then plan the figure accordingly. Photographs should be near to their printed size as possible. If magnification is required, it should be indicated by a bar on the print, not by a magnification factor.

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.